Biolase (Biolase) Retained Earnings : $-316.80 Mil (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is Biolase Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Biolase's retained earnings for the quarter that ended in Dec. 2023 was $-316.80 Mil.

Biolase's quarterly retained earnings declined from Jun. 2023 ($-306.89 Mil) to Sep. 2023 ($-311.47 Mil) and declined from Sep. 2023 ($-311.47 Mil) to Dec. 2023 ($-316.80 Mil).

Biolase's annual retained earnings declined from Dec. 2021 ($-267.53 Mil) to Dec. 2022 ($-296.17 Mil) and declined from Dec. 2022 ($-296.17 Mil) to Dec. 2023 ($-316.80 Mil).

Biolase Retained Earnings Historical Data

The historical data trend for Biolase's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biolase Retained Earnings Chart

Biolase Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-234.55

-251.38

-267.53

-296.17

-316.80

Biolase Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Retained Earnings	Get a 7-Day Free Trial															-296.17	-302.02	-306.89	-311.47	-316.80

Biolase Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Biolase (NAS:BIOL) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Biolase (Biolase) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biolase Inc (NAS:BIOL) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

BTH0:Germany

Address

27042 Towne Centre Drive, Suite 270, Lake Forest, CA, USA, 92610

Website

https://www.biolase.com

Biolase Inc is a US-based medical device company. It develops, manufactures, markets, and sells laser systems in dentistry and medicine. The company also markets, sells and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intraoral scanners. It offers two categories of laser system products: Waterlase (all-tissue) systems and Diode (soft-tissue) systems which allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The majority of the company's revenue comes from the United States.

Executives

Goldman Sachs & Co. Llc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
Goldman Sachs Group Inc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
Lord Jonathan T Md	director	500 WEST MAIN ST., LOUISVILLE KY 40202
Jennifer Bright	officer: Chief Financial Officer	27042 TOWNE CENTRE DRIVE,, SUITE 270, FOOTHILL RANCH CA 92610
Steven Sandor	officer: Chief Operating Officer	27042 TOWNE CENTRE DRIVE,, SUITE 270, FOOTHILL RANCH CA 92610
Jess Roper	director	5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Kenneth P. Yale	director	27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
John R Beaver	director, officer: President & CEO	C/O STERLING CHEMICALS INC, 1200 SMITH STREET, HOUSTON TX 77002
Kathleen T Oloughlin	director	27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
Somerman Martha J. Dds, Phd	director	27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
Summerhays Carol Gomez Dds	director	27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
Family Foundation Schuler	10 percent owner	100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Larry N Feinberg	10 percent owner	C/O ORACLE PARTNERS L P, 200 GREENWICH AVENUE, GREENWICH CT 06830
Jack W Schuler	10 percent owner	100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Michael Ditolla	director	3299 CAMBRIDGE AVE, BRONX NY 10463